Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease

Purpose Alcohol consumption is a leading cause of morbidity and mortality in our society and alcohol-related liver disease is a major contributor to this. Abstinence is the most important treatment goal for patients with alcohol-related liver disease and appropriate pharmacotherapy can help to achie...

Full description

Saved in:
Bibliographic Details
Published in:Current addiction reports 2018-06, Vol.5 (2), p.287-296
Main Authors: Stoklosa, Ted M., Morley, Kirsten C., Volovets, Anastasia, Haber, Paul S.
Format: Article
Language:English
Subjects:
Alcohol (M Farrell and E Stockings
Alcohol use
Anorexia
Ascites
Asymptomatic
Comorbidity
Drug therapy
Hepatitis
Inflammation
Liver cancer
Liver cirrhosis
Liver diseases
Liver transplants
Medicine
Medicine & Public Health
Mental disorders
Mental health
Metabolism
Metabolites
Mortality
Neurology
Neurosciences
Oxidative stress
Pathogenesis
Primary care
Psychiatry
Risk factors
Section Editors
Substance abuse treatment
Topical Collection on Alcohol
Vitamin deficiency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Alcohol consumption is a leading cause of morbidity and mortality in our society and alcohol-related liver disease is a major contributor to this. Abstinence is the most important treatment goal for patients with alcohol-related liver disease and appropriate pharmacotherapy can help to achieve this. Recent findings There are a number of established and emerging pharmacotherapies for the treatment of alcohol use disorder that can be used in patients with liver disease although few have been studied extensively in this population. There are conflicting data on the effectiveness of these therapies and alcohol pharmacotherapy is an evolving field where more research is needed. The only effective treatment for alcoholic liver disease is abstinence. Summary High-quality comparative studies of pharmacotherapies and further inclusion of patients with comorbidity are needed. While current pharmacotherapies are of modest effect, many can be safely used in patients with alcoholic liver disease which is a major cause of morbidity and mortality where the only effective treatment is abstinence.
ISSN:2196-2952
2196-2952
DOI:10.1007/s40429-018-0211-1